Goldman Sachs Group Inc. Boosts Stock Holdings in Axonics, Inc. (NASDAQ:AXNX)

Goldman Sachs Group Inc. boosted its position in Axonics, Inc. (NASDAQ:AXNX) by 6.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 621,570 shares of the company’s stock after purchasing an additional 40,306 shares during the period. Goldman Sachs Group Inc. owned about 1.23% of Axonics worth $38,680,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of AXNX. NBC Securities Inc. raised its holdings in Axonics by 106.4% during the 4th quarter. NBC Securities Inc. now owns 673 shares of the company’s stock valued at $41,000 after acquiring an additional 347 shares during the period. Headlands Technologies LLC bought a new stake in Axonics during the 4th quarter valued at $53,000. RiverPark Advisors LLC raised its holdings in Axonics by 14.4% during the 4th quarter. RiverPark Advisors LLC now owns 1,185 shares of the company’s stock valued at $74,000 after acquiring an additional 149 shares during the period. C M Bidwell & Associates Ltd. raised its holdings in Axonics by 108.2% during the 3rd quarter. C M Bidwell & Associates Ltd. now owns 1,270 shares of the company’s stock valued at $71,000 after acquiring an additional 660 shares during the period. Finally, Sentry Investment Management LLC bought a new stake in Axonics during the 4th quarter valued at $125,000. Hedge funds and other institutional investors own 99.48% of the company’s stock.

Axonics Stock Up 0.4 %

AXNX opened at $67.57 on Friday. The stock has a market cap of $3.45 billion, a PE ratio of -211.16 and a beta of 0.90. Axonics, Inc. has a 52 week low of $47.94 and a 52 week high of $69.68. The business’s fifty day simple moving average is $67.19 and its 200 day simple moving average is $66.37.

Axonics (NASDAQ:AXNX) last released its earnings results on Tuesday, April 30th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.32). The firm had revenue of $91.41 million during the quarter, compared to the consensus estimate of $89.79 million. Axonics had a negative net margin of 4.12% and a negative return on equity of 2.58%. The firm’s revenue was up 29.4% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.19) EPS. As a group, equities analysts anticipate that Axonics, Inc. will post 0.13 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on AXNX shares. Royal Bank of Canada reissued a “sector perform” rating and set a $71.00 target price on shares of Axonics in a report on Thursday, February 29th. Needham & Company LLC reaffirmed a “hold” rating on shares of Axonics in a report on Monday, May 6th. Eight analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, Axonics presently has an average rating of “Hold” and a consensus target price of $70.30.

Axonics Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.